西妥昔单抗联合放疗治疗头颈癌 - Suppr

Suppr

超能文献

Cetuximab plus radiotherapy for head and neck cancer.

作者信息

Armstrong John G

出版信息

N Engl J Med. 2006 May 18;354(20):2187; author reply 2187.

PMID:16710907

Abstract

摘要

相似文献

Cetuximab plus radiotherapy for head and neck cancer.

N Engl J Med. 2006 May 18;354(20):2187; author reply 2187.

Cetuximab plus radiotherapy for head and neck cancer.

N Engl J Med. 2006 May 18;354(20):2187; author reply 2187.

Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer.

Clin Oncol (R Coll Radiol). 2008 Nov;20(9):717. doi: 10.1016/j.clon.2008.07.003. Epub 2008 Aug 30.

Cetuximab plus radiotherapy for head and neck cancer.

N Engl J Med. 2006 May 18;354(20):2187; author reply 2187. doi: 10.1056/NEJMc060694.

Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer.

Radiother Oncol. 2009 Dec;93(3):654. doi: 10.1016/j.radonc.2009.05.005. Epub 2009 Jun 11.

Cetuximab and radiotherapy for head and neck cancer.

N Engl J Med. 2006 Feb 9;354(6):634-6. doi: 10.1056/NEJMe058306.

Cetuximab plus radiotherapy for head and neck cancer.

N Engl J Med. 2006 May 18;354(20):2187; author reply 2187.

More on cetuximab in head and neck cancer.

N Engl J Med. 2007 Nov 22;357(21):2201-2; author reply 2202-3. doi: 10.1056/NEJMc071540.

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

N Engl J Med. 2006 Feb 9;354(6):567-78. doi: 10.1056/NEJMoa053422.

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Lancet Oncol. 2010 Jan;11(1):21-8. doi: 10.1016/S1470-2045(09)70311-0. Epub 2009 Nov 10.

引用本文的文献

Insights into ovarian cancer: chemo-diversity, dose depended toxicities and survival responses.

Med Oncol. 2023 Mar 4;40(4):111. doi: 10.1007/s12032-023-01976-0.

Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.

Cochrane Database Syst Rev. 2021 Dec 20;12(12):CD006386. doi: 10.1002/14651858.CD006386.pub4.

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.

Cochrane Database Syst Rev. 2015 Dec 1;2015(12):CD010341. doi: 10.1002/14651858.CD010341.pub2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Cetuximab plus radiotherapy for head and neck cancer.

N Engl J Med. 2006 May 18;354(20):2187; author reply 2187.

Cetuximab plus radiotherapy for head and neck cancer.

N Engl J Med. 2006 May 18;354(20):2187; author reply 2187.

Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer.

Clin Oncol (R Coll Radiol). 2008 Nov;20(9):717. doi: 10.1016/j.clon.2008.07.003. Epub 2008 Aug 30.

Cetuximab plus radiotherapy for head and neck cancer.

N Engl J Med. 2006 May 18;354(20):2187; author reply 2187. doi: 10.1056/NEJMc060694.

Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer.

Radiother Oncol. 2009 Dec;93(3):654. doi: 10.1016/j.radonc.2009.05.005. Epub 2009 Jun 11.

Cetuximab and radiotherapy for head and neck cancer.

N Engl J Med. 2006 Feb 9;354(6):634-6. doi: 10.1056/NEJMe058306.

Cetuximab plus radiotherapy for head and neck cancer.

N Engl J Med. 2006 May 18;354(20):2187; author reply 2187.

More on cetuximab in head and neck cancer.

N Engl J Med. 2007 Nov 22;357(21):2201-2; author reply 2202-3. doi: 10.1056/NEJMc071540.

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

N Engl J Med. 2006 Feb 9;354(6):567-78. doi: 10.1056/NEJMoa053422.

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Lancet Oncol. 2010 Jan;11(1):21-8. doi: 10.1016/S1470-2045(09)70311-0. Epub 2009 Nov 10.

引用本文的文献

Insights into ovarian cancer: chemo-diversity, dose depended toxicities and survival responses.

Med Oncol. 2023 Mar 4;40(4):111. doi: 10.1007/s12032-023-01976-0.

Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.

Cochrane Database Syst Rev. 2021 Dec 20;12(12):CD006386. doi: 10.1002/14651858.CD006386.pub4.

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.

Cochrane Database Syst Rev. 2015 Dec 1;2015(12):CD010341. doi: 10.1002/14651858.CD010341.pub2.